Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

735 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing.
Ptashkin RN, Ewalt MD, Jayakumaran G, Kiecka I, Bowman AS, Yao J, Casanova J, Lin YD, Petrova-Drus K, Mohanty AS, Bacares R, Benhamida J, Rana S, Razumova A, Vanderbilt C, Balakrishnan Rema A, Rijo I, Son-Garcia J, de Bruijn I, Zhu M, Lachhander S, Wang W, Haque MS, Seshan VE, Wang J, Liu Y, Nafa K, Borsu L, Zhang Y, Aypar U, Suehnholz SP, Chakravarty D, Park JH, Abdel-Wahab O, Mato AR, Xiao W, Roshal M, Yabe M, Batlevi CL, Giralt S, Salles G, Rampal R, Tallman M, Stein EM, Younes A, Levine RL, Perales MA, van den Brink MRM, Dogan A, Ladanyi M, Berger MF, Brannon AR, Benayed R, Zehir A, Arcila ME. Ptashkin RN, et al. Among authors: younes a. Nat Commun. 2023 Oct 28;14(1):6895. doi: 10.1038/s41467-023-42585-9. Nat Commun. 2023. PMID: 37898613 Free PMC article.
Novel immunotherapies in lymphoid malignancies.
Batlevi CL, Matsuki E, Brentjens RJ, Younes A. Batlevi CL, et al. Among authors: younes a. Nat Rev Clin Oncol. 2016 Jan;13(1):25-40. doi: 10.1038/nrclinonc.2015.187. Epub 2015 Nov 3. Nat Rev Clin Oncol. 2016. PMID: 26525683 Free PMC article. Review.
Novel therapy for Hodgkin lymphoma.
Batlevi CL, Younes A. Batlevi CL, et al. Among authors: younes a. Hematology Am Soc Hematol Educ Program. 2013;2013:394-9. doi: 10.1182/asheducation-2013.1.394. Hematology Am Soc Hematol Educ Program. 2013. PMID: 24319210 Review.
Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting.
He J, Abdel-Wahab O, Nahas MK, Wang K, Rampal RK, Intlekofer AM, Patel J, Krivstov A, Frampton GM, Young LE, Zhong S, Bailey M, White JR, Roels S, Deffenbaugh J, Fichtenholtz A, Brennan T, Rosenzweig M, Pelak K, Knapp KM, Brennan KW, Donahue AL, Young G, Garcia L, Beckstrom ST, Zhao M, White E, Banning V, Buell J, Iwanik K, Ross JS, Morosini D, Younes A, Hanash AM, Paietta E, Roberts K, Mullighan C, Dogan A, Armstrong SA, Mughal T, Vergilio JA, Labrecque E, Erlich R, Vietz C, Yelensky R, Stephens PJ, Miller VA, van den Brink MR, Otto GA, Lipson D, Levine RL. He J, et al. Among authors: younes a. Blood. 2016 Jun 16;127(24):3004-14. doi: 10.1182/blood-2015-08-664649. Epub 2016 Mar 10. Blood. 2016. PMID: 26966091 Free PMC article.
Revival of PI3K inhibitors in non-Hodgkin's lymphoma.
Batlevi CL, Younes A. Batlevi CL, et al. Among authors: younes a. Ann Oncol. 2017 Sep 1;28(9):2047-2049. doi: 10.1093/annonc/mdx392. Ann Oncol. 2017. PMID: 28911078 Free article. No abstract available.
Surrogate end points in lymphoma.
Batlevi CL, Younes A. Batlevi CL, et al. Among authors: younes a. Ann Oncol. 2018 Aug 1;29(8):1622-1623. doi: 10.1093/annonc/mdy219. Ann Oncol. 2018. PMID: 29905757 Free article. No abstract available.
TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma.
Erazo T, Evans CM, Zakheim D, Chu KL, Refermat AY, Asgari Z, Yang X, Da Silva Ferreira M, Mehta S, Russo MV, Knezevic A, Zhang XP, Chen Z, Fennell M, Garippa R, Seshan V, de Stanchina E, Barbash O, Batlevi CL, Leslie CS, Melnick AM, Younes A, Kharas MG. Erazo T, et al. Among authors: younes a. Nat Commun. 2022 Sep 27;13(1):5676. doi: 10.1038/s41467-022-33137-8. Nat Commun. 2022. PMID: 36167829 Free PMC article.
Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay.
Intlekofer AM, Joffe E, Batlevi CL, Hilden P, He J, Seshan VE, Zelenetz AD, Palomba ML, Moskowitz CH, Portlock C, Straus DJ, Noy A, Horwitz SM, Gerecitano JF, Moskowitz A, Hamlin P, Matasar MJ, Kumar A, van den Brink MR, Knapp KM, Pichardo JD, Nahas MK, Trabucco SE, Mughal T, Copeland AR, Papaemmanuil E, Moarii M, Levine RL, Dogan A, Miller VA, Younes A. Intlekofer AM, et al. Among authors: younes a. Blood Cancer J. 2018 Jun 12;8(6):60. doi: 10.1038/s41408-018-0089-0. Blood Cancer J. 2018. PMID: 29895903 Free PMC article.
Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study.
Qualls D, Noy A, Straus D, Matasar M, Moskowitz C, Seshan V, Dogan A, Salles G, Younes A, Zelenetz AD, Batlevi CL. Qualls D, et al. Among authors: younes a. Leuk Lymphoma. 2023 Mar;64(3):738-741. doi: 10.1080/10428194.2022.2164194. Epub 2023 Jan 15. Leuk Lymphoma. 2023. PMID: 36642966 Free PMC article. Clinical Trial. No abstract available.
735 results